Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 targeting CAR T cells
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
B7-H3 targeting CAR T cells are an investigational cell therapy modality designed to treat solid tumors by targeting the CD276 (B7-H3) antigen. B7-H3 is a transmembrane protein in the B7 family that is highly expressed in various malignancies, including glioblastoma, neuroblastoma, and several carcinomas, while having limited expression in normal tissues. These CAR T cells are engineered to recognize B7-H3, triggering T-cell activation and direct cytolysis of tumor cells. Advanced iterations of this platform, such as those developed by researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, incorporate armoring strategies—such as the secretion of PD-1 blocking scFvs—to counteract immunosuppressive signals in the tumor microenvironment and enhance persistence and efficacy in challenging indications like glioblastoma.
- Other names
- B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TCD276-targeted CAR-T cellsCD-276-targeted CAR-T cellsCD 276-targeted CAR-T cellsB7-H3-specific CAR T cellsB-7-H3-specific CAR T cellsB 7-H3-specific CAR T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 targeting CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 targeting CAR T cells.